A Phase 4 interventional study of Apixaban in Non-valvular Atrial Fibrillation, sponsored by Bristol-Myers Squibb. Completed at 223 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-08-19.
Sponsored by Bristol-Myers Squibb · Phase 4, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 31 studies testing apixaban in Atrial Fibrillation — 11 open to participants now, 12 under way, 4 of them phase 3. apixaban · Atrial Fibrillation.
Among the 31 studies testing apixaban in Atrial Fibrillation, this one is the 9th largest by enrollment, is the only one that started in 2013, is one of 14 in phase 4, and was the 4th registered.
4,011 studies on the registry are indexed under Atrial Fibrillation; 961 are open to participants now.
Browse Atrial Fibrillation studies →11 of the 31 studies testing apixaban in Atrial Fibrillation are open now, in 10 countries. Recruiting first, the newest first:
Yonsei University · Sites in Korea, Republic of
Ages 19+
VA Office of Research and Development · Sites in United States
Ages 22+
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 65+
Ottawa Hospital Research Institute · Sites in Canada
Ages 18+
Yonsei University · Sites in Korea, Republic of
Ages 19–80
By country, each count listing its studies:
apixaban: first FDA approval 2012 (ELIQUIS), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →
Of the 611 Atrial Fibrillation studies recruiting now, 407 (67%) set no upper age limit and 43 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
31 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 1 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,217 is above the median of 150 across 2,477 interventional studies indexed under Atrial Fibrillation.
Median enrollment 586 across the 31 interventional studies. Of the 17 that completed or were terminated, 9 (53%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 31 have an industry lead sponsor. The 10 most frequent:
Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
33 studies in Atrial Fibrillation by Bristol-Myers Squibb: none open now, none under way, none of them phase 3. Of 30 finished, 4 (13%) have results posted.
Among the 33 studies in Atrial Fibrillation by Bristol-Myers Squibb, this one is the 5th largest by enrollment of the 11 interventional ones that give a count, is one of 4 that started in 2013, is one of 2 in phase 4, and was the 7th registered.
Bristol-Myers Squibb’s Atrial Fibrillation studies by the year they started, since 2006.
2 of the studies testing apixaban in Atrial Fibrillation that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03907046Phase 3Yale UniversityAnticoagulation in ICH Survivors for Stroke Prevention and Recovery | 2027-04 |
| NCT03129490Herlev and Gentofte HospitalThe Danish Non-vitamin K Antagonist Oral Anticoagulation Study in Patients With Atrial Fibrillation | 2027-10-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 31 studies testing apixaban in Atrial Fibrillation, from their registry updates:
Among Bristol-Myers Squibb’s 33 in Atrial Fibrillation:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The study purpose is to assess the impact of an educational program on patient adherence in patients taking Apixaban for SPAF at 24 weeks
SPAF=Stroke Prevention in Atrial Fibrillation
ISTH=International Society on Thrombosis and Hemostasis
Primary Purpose: Other: To measure adherence to the study medication using an electronic monitoring device over the first 24 weeks on study medication
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Presence of at least one of the following risk factors for stroke:
Prior stroke or (TIA)
Age and Reproductive Status:
Exclusion Criteria:
Target Disease Exceptions:
Medical History and Concurrent Diseases:
Patient with serious bleeding in the last 6 months or with a lesion or condition at high risk of bleeding such as:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Apixaban 2.5 mg or 5 mg by mouth twice daily for 48 weeks and Primary Standard of Care (SOC) information
Drug: Apixaban
Apixaban 2.5 mg or 5 mg by mouth twice daily for 48 weeks and Additional Educational Program
Drug: Apixaban
Also known as: Eliquis, BMS-562247
Percentage of Days With a Correct Execution of the Apixaban Dosing Regimen
The mean percentage of days which participants maintained adherence to apixaban treatment was measured for each arm. Adherence to apixaban = number of units of adherence \*100 / total number of eligible days for the time period from first dose date, up to 169 days. Unit of adherence: A 24-hour window where the treatment is taken as prescribed, ie, 1 tablet (5 mg or 2.5 mg, as appropriate) 2 times a day. If only one dose is missed in 24-hours, it is still considered as a unit of adherence. Adherence up to 24 weeks was calculated as the percentage of adherence units within that period. If a participant discontinued from the study before 24 weeks, the denominator time period was censored at the earlier of last dose date or discontinuation date for discontinuation due to reasons unrelated to participant adherence, such as withdrawn consent, or AE; otherwise, the period was censored at the minimum of 169 days and last dose date + 30 days.
Time frame: Day 1 up to week 24
Percentage of Days With a Correct Execution of the Apixaban Dosing Regimen During the 12 to 24 Weeks Period Compared With During the First 12 Weeks
The mean adherence to apixaban treatment during the first 24 weeks was measured between the standard of care (SOC) information and Additional Education Program (AEP) arms and expressed as a percentage. Adherence to Apixaban = number of units of adherence \*100 / total number of eligible days for the time period.
Time frame: Day 1 to Week 12, Week 12 to Week 24
Percentage of Days With a Correct Execution of the Apixaban Dosing Regimen During the 24 to 48 Weeks Period
The mean percentage of days which participants maintained adherence to apixaban treatment was measured for each arm. Adherence to apixaban = number of units of adherence \*100 / total number of eligible days for the time period from first dose date, up to 169 days. Unit of adherence: A 24-hour window where the treatment is taken as prescribed, ie, 1 tablet (5 mg or 2.5 mg, as appropriate) 2 times a day. If only one dose is missed in 24-hours, it is still considered as a unit of adherence. Adherence over 24 weeks was calculated as the percentage of adherence units within that period. If a participant discontinued from the study before 48 weeks, the denominator time period was censored at the earlier of last dose date or discontinuation date for discontinuation due to reasons unrelated to participant adherence, such as withdrawn consent, or AE; otherwise, the period was censored at the minimum of 169 days and last dose date + 30 days.
Time frame: Week 24 to Week 48
Non-adherence Predictors of 20% or More (vs. at Least 80% Adherence) at 24 Weeks
Logit analyses were conducted on the Primary Efficacy Set to identify non-adherence predictors of 20% or more (vs. at least 80% adherence) at 24 weeks. In the Primary SOC group, alcohol use, Mini-Mental State Evaluation (MMSE) score, UK standard occupational classification, and type of atrial fibrillation were retained in the model (p-value \<= 0.2). In the Additional Educational Program group, alcohol use, type of atrial fibrillation, age and Vitamin K Antagonists (VKA) status were retained in the model (p-value \<= 0.2). Odds ratios are presented for predictors of non-adherence.
Time frame: Week 24
Number of Participants With Serious Adverse Events (SAEs), Drug Related Adverse Events (AE), AE Leading to Discontinuation, and Death
AEs with onset date from day 1 through week 24 are included in this summary. AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Treatment-related=having certain, probable, possible, or missing relationship to study drug.
Time frame: Day 1 up to week 24
Number of Participants With Serious Adverse Events (SAEs), Drug Related Adverse Events (AE), AE Leading to Discontinuation, and Death
Adverse events with onset date after 24 weeks are included in this summary. AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Treatment-related=having certain, probable, possible, or missing relationship to study drug.
Time frame: Week 24 up to Week 48
| Milestone | Apixaban (Primary SOC) | Apixaban (Additional Educational Program) | Apixaban (Secondary SOC) |
|---|---|---|---|
| Started | 583 | 579 | 0 |
| Safety analysis set | 604 | 558 | 0 |
| Completed | 529 | 525 | 0 |
| Not completed | 54 | 54 | 0 |
| Withdrew: Subject withdrew consent | 17 | 20 | 0 |
| Withdrew: Death | 6 | 4 | 0 |
| Withdrew: Lost to follow-up | 0 | 1 | 0 |
| Withdrew: Serious adverse event | 7 | 6 | 0 |
| Withdrew: Adverse event | 15 | 11 | 0 |
| Withdrew: Drug interruption >30 consecutive days | 0 | 2 | 0 |
| Withdrew: Inclusion/exclusion criterion | 2 | 5 | 0 |
| Withdrew: Helping hand not used | 2 | 0 | 0 |
| Withdrew: Helping hand not used, treatment taken | 1 | 1 | 0 |
| Withdrew: Withdrawal by subject | 1 | 1 | 0 |
| Withdrew: Medical reason | 3 | 3 | 0 |
| Milestone | Apixaban (Primary SOC) | Apixaban (Additional Educational Program) | Apixaban (Secondary SOC) |
|---|---|---|---|
| Started | 583 | 263 | 261 |
| Safety analysis set | 604 | 308 | 223 |
| Completed | 503 | 250 | 250 |
| Not completed | 80 | 13 | 11 |
| Withdrew: Subject withdrew consent | 21 | 0 | 2 |
| Withdrew: Death | 7 | 3 | 3 |
| Withdrew: Lost to follow-up | 1 | 0 | 1 |
| Withdrew: Serious adverse event | 17 | 6 | 3 |
| Withdrew: Adverse event | 17 | 3 | 0 |
| Withdrew: Drug interruption >30 consecutive days | 3 | 0 | 2 |
| Withdrew: Helping hand not used | 4 | 0 | 0 |
| Withdrew: Helping hand not used, treatment taken | 3 | 0 | 0 |
| Withdrew: Medical reason | 4 | 1 | 0 |
| Withdrew: Subject decision | 1 | 0 | 0 |
| Withdrew: Inclusion / exclusion criterion | 2 | 0 | 0 |
The mean percentage of days which participants maintained adherence to apixaban treatment was measured for each arm. Adherence to apixaban = number of units of adherence \*100 / total number of eligible days for the time period from first dose date, up to 169 days. Unit of adherence: A 24-hour window where the treatment is taken as prescribed, ie, 1 tablet (5 mg or 2.5 mg, as appropriate) 2 times a day. If only one dose is missed in 24-hours, it is still considered as a unit of adherence. Adherence up to 24 weeks was calculated as the percentage of adherence units within that period. If a participant discontinued from the study before 24 weeks, the denominator time period was censored at the earlier of last dose date or discontinuation date for discontinuation due to reasons unrelated to participant adherence, such as withdrawn consent, or AE; otherwise, the period was censored at the minimum of 169 days and last dose date + 30 days.
| percentage of days | Apixaban (Primary SOC Information) | Apixaban (Additional Educational Program) |
|---|---|---|
| Percentage of Days With a Correct Execution of the Apixaban Dosing Regimen | 91.64 ± 17.143 | 91.88 ± 16.140 |
The mean adherence to apixaban treatment during the first 24 weeks was measured between the standard of care (SOC) information and Additional Education Program (AEP) arms and expressed as a percentage. Adherence to Apixaban = number of units of adherence \*100 / total number of eligible days for the time period.
| percentage | Apixaban (Primary SOC Information) | Apixaban (Additional Educational Program) |
|---|---|---|
| Day 1 to Week 12 | 93.7 ± 14.18 | 93.0 ± 15.71 |
| Week 12 to Week 24 | 90.3 ± 20.64 | 90.9 ± 18.36 |
The mean percentage of days which participants maintained adherence to apixaban treatment was measured for each arm. Adherence to apixaban = number of units of adherence \*100 / total number of eligible days for the time period from first dose date, up to 169 days. Unit of adherence: A 24-hour window where the treatment is taken as prescribed, ie, 1 tablet (5 mg or 2.5 mg, as appropriate) 2 times a day. If only one dose is missed in 24-hours, it is still considered as a unit of adherence. Adherence over 24 weeks was calculated as the percentage of adherence units within that period. If a participant discontinued from the study before 48 weeks, the denominator time period was censored at the earlier of last dose date or discontinuation date for discontinuation due to reasons unrelated to participant adherence, such as withdrawn consent, or AE; otherwise, the period was censored at the minimum of 169 days and last dose date + 30 days.
| percentage | Apixaban (Primary SOC Information) | Apixaban (Additional Educational Program) | Apixaban (Secondary SOC) |
|---|---|---|---|
| Percentage of Days With a Correct Execution of the Apixaban Dosing Regimen During the 24 to 48 Weeks Period | 87.59 ± 22.921 | 88.41 ± 22.148 | 87.51 ± 21.125 |
Logit analyses were conducted on the Primary Efficacy Set to identify non-adherence predictors of 20% or more (vs. at least 80% adherence) at 24 weeks. In the Primary SOC group, alcohol use, Mini-Mental State Evaluation (MMSE) score, UK standard occupational classification, and type of atrial fibrillation were retained in the model (p-value \<= 0.2). In the Additional Educational Program group, alcohol use, type of atrial fibrillation, age and Vitamin K Antagonists (VKA) status were retained in the model (p-value \<= 0.2). Odds ratios are presented for predictors of non-adherence.
| Odds ratio | Apixaban (Primary SOC Information) | Apixaban (Additional Educational Program) |
|---|---|---|
| <=2 Alcoholic Drink/Day Average vs None | 1.251 (0.691 to 2.265) | 0.994 (0.558 to 1.682) |
| >=3 Alcoholic Drink/Day Average vs None | 4.268 (1.226 to 14.859) | 3.782 (0.884 to 16.178) |
| Mini-mental state examination score | 0.808 (0.686 to 0.952) | NA (NA to NA) |
| Higher mgmt., adm. and professional jobs vs UKSOC1 | 0.827 (0.136 to 5.033) | NA (NA to NA) |
| Higher professional occupations vs UKSOC1 | 0.898 (0.197 to 4.091) | NA (NA to NA) |
| Intermediate occupations vs UKSOC1 | 1.230 (0.401 to 3.769) | NA (NA to NA) |
| Large employers and mgmt. and adm. jobs vs UKSOC1 | 2.823 (0.412 to 19.338) | NA (NA to NA) |
| Lower mgmt., adm. and professional jobs vs UKSOC1 | 0.948 (0.256 to 3.515) | NA (NA to NA) |
| Lower supervisory and tech. occupations vs UKSOC1 | 3.587 (1.008 to 12.766) | NA (NA to NA) |
| Never worked and long-term unemployed vs UKSOC1 | 1.289 (0.419 to 3.962) | NA (NA to NA) |
| Routine occupations vs UKSOC1 | 0.508 (0.181 to 1.425) | NA (NA to NA) |
| Semi-routine occupations vs UKSOC1 | 0.450 (0.083 to 2.453) | NA (NA to NA) |
| Paroxysmal vs Persistant Atrial Fibrillation | 1.626 (0.766 to 3.453) | 1.911 (0.940 to 3.885) |
| Permanent vs Persistant Atrial Fibrillation | 2.560 (1.152 to 5.688) | 1.846 (0.819 to 4.158) |
| VKA Naïve vs Non-Naïve | NA (NA to NA) | 1.686 (0.932 to 3.049) |
AEs with onset date from day 1 through week 24 are included in this summary. AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Treatment-related=having certain, probable, possible, or missing relationship to study drug.
| Participants | Apixaban (Primary SOC Information) | Apixaban (Additional Educational Program) |
|---|---|---|
| SAE | 75 | 82 |
| Drug related AE | 54 | 41 |
| AE leading to discontinuation | 33 | 22 |
| Death | 6 | 5 |
Adverse events with onset date after 24 weeks are included in this summary. AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Treatment-related=having certain, probable, possible, or missing relationship to study drug.
| Participants | Apixaban (Primary SOC Information) | Apixaban (Additional Educational Program) | Apixaban (Secondary SOC) |
|---|---|---|---|
| SAE | 71 | 43 | 30 |
| Drug related AE | 15 | 12 | 10 |
| AE leading to discontinuation | 14 | 3 | 8 |
| Death | 3 | 3 | 6 |
Collected over From date of first dose to date of last dose plus 30 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Primary SOC (Period 1) | — | 69/604 (11.4%) | 40/604 (6.6%) |
| Continued Additional Educational Program (CAEP) (Period 2) | — | 40/308 (13%) | 5/308 (1.6%) |
| Secondary SOC (Period 2) | — | 29/223 (13%) | 5/223 (2.2%) |
| Additional Educational Program (Period 1) | — | 79/558 (14.2%) | 46/558 (8.2%) |
| Primary SOC (Period 2) | — | 62/604 (10.3%) | 21/604 (3.5%) |
| Event | Primary SOC (Period 1) | Continued Additional Educational Program (CAEP) (Period 2) | Secondary SOC (Period 2) | Additional Educational Program (Period 1) | Primary SOC (Period 2) |
|---|---|---|---|---|---|
| Cardiac failureCardiac disorders | 9/604 | 3/308 | 1/223 | 13/558 | 4/604 |
| Atrial fibrillationCardiac disorders | 7/604 | 0/308 | 1/223 | 10/558 | 3/604 |
| Cardiac ablationSurgical and medical procedures | 8/604 | 1/308 | 0/223 | 3/558 | 3/604 |
| Myocardial infarctionCardiac disorders | 0/604 | 0/308 | 2/223 | 2/558 | 0/604 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 0/604 | 1/308 | 2/223 | 4/558 | 1/604 |
| PneumoniaInfections and infestations | 5/604 | 1/308 | 2/223 | 3/558 | 2/604 |
| HypertensionVascular disorders | 1/604 | 2/308 | 0/223 | 0/558 | 1/604 |
| Angina pectorisCardiac disorders | 1/604 | 2/308 | 1/223 | 2/558 | 0/604 |
| Chronic obstructive pulmonaryRespiratory, thoracic and mediastinal disorders | 1/604 | 2/308 | 0/223 | 1/558 | 1/604 |
| Infective exacerbation of chronic obstructive airways diseaseInfections and infestations | 0/604 | 2/308 | 0/223 | 0/558 | 1/604 |
| Event | Primary SOC (Period 1) | Continued Additional Educational Program (CAEP) (Period 2) | Secondary SOC (Period 2) | Additional Educational Program (Period 1) | Primary SOC (Period 2) |
|---|---|---|---|---|---|
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 40/604 | 5/308 | 5/223 | 46/558 | 21/604 |
Primary Efficacy Analysis Set (24 week)
| Age, Continuous(years) | Apixaban (Primary SOC Information) | Apixaban (Additional Educational Program) | Total |
|---|---|---|---|
| Mean | 72.6 ± 8.94 | 73.1 ± 9.05 | 72.9 ± 9.00 |
| Age, Customized(Participants) | Apixaban (Primary SOC Information) | Apixaban (Additional Educational Program) | Total |
|---|---|---|---|
| <64 years | 86 | 77 | 163 |
| 64-74 years | 221 | 220 | 441 |
| >=75 years | 276 | 282 | 558 |
| Sex: Female, Male(Participants) | Apixaban (Primary SOC Information) | Apixaban (Additional Educational Program) | Total |
|---|---|---|---|
| Female | 232 | 234 | 466 |
| Male | 351 | 345 | 696 |
Showing the first 100 of 223 sites across 7 countries. Choose a country and city above to see the rest.
Ran from Oct 2013 to primary completion in Jan 2016, 27 months.
Results were first posted in Aug 2019, 3 years 6 months after primary completion.
Of 141 phase 4 interventional studies under Atrial Fibrillation, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 81. This study's 27 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Apixaban